EBOS Group (EBO) investor relations material

Opening remarks and agenda

• Auckland meeting held in person and online; quorum confirmed and voting opened by poll on all business.

• Annual report, FY26 financial statements and audit report received; resolutions covered Julie Tay’s re-election and authorization for directors to set Deloitte’s fees.

Financial performance review

• FY26 revenue was A$13,487m, up 9.9%; underlying EBITDA was A$614m, up 5.0%, and all guidance metrics were met.

• Underlying NPAT was A$250m, down 3.1%; underlying EPS was 121.7 cents, down 7.3%; statutory EBITDA increased 8%.

• All eight new facilities were operational by 30 June 2026, completing the major investment cycle; FY26 capex was A$145m.

• Net leverage was 2.1x within the 1.7x–2.3x target range; ROCE was 12.8%, down 20 bps.

• FY27 guidance reaffirmed: underlying EBITDA A$635m–A$655m, capex ~A$100m, D&A A$152m–A$162m and net finance costs A$138m–A$148m; EBITDA and NPAT growth expected to skew to H2.

Board and executive committee updates

• Julie Tay, an independent director appointed in May 2023, sought re-election after three years on the board; her experience includes senior roles at Align Technology, Bayer Healthcare, Johnson Diversey and Johnson & Johnson.

• From FY27, executive remuneration defers part of short-term incentives into equity, adds market-priced options to long-term incentives and sets minimum executive shareholding requirements.

• Non-executive directors adopted a minimum shareholding policy; each director bought shares during FY26.